Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · GoodRx Holdings, Inc. (GDRX)

GoodRx Q2 revenue falls 1% to $200.4 million as company raises 2026 guidance

Mixed Impact 4 of 5 guidance Written later

GoodRx reported second-quarter 2026 revenue of $200.4 million, down 1% from $203.1 million, and net income of $8.5 million, down from $12.8 million. The company raised its full-year 2026 revenue guidance to $790 million to $805 million and its Adjusted EBITDA guidance to $240 million to $250 million, citing Pharma Direct and subscription growth.

Key points

  • Revenue was $200.4 million versus $203.1 million; net income was $8.5 million versus $12.8 million, and net income margin was 4.3% versus 6.3%.
  • Prescription transactions revenue fell 26% to $106.4 million, while Pharma Direct revenue rose 76% to $61.6 million and subscription revenue rose 39% to $28.5 million.
  • Adjusted EBITDA was $63.7 million versus $69.4 million, and net cash from operating activities was $80.8 million versus $49.6 million.
  • Full-year 2026 guidance: revenue of $790 million to $805 million and Adjusted EBITDA of $240 million to $250 million, compared with FY 2025 revenue of $796.9 million.

The filing

CompanyGoodRx Holdings, Inc. (GDRX)
Form8-K, current report
Filed with the SECAug 5, 2026, 4:07 PM ET
Accession number0001809519-26-000151

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.